ロード中...
Predicting development of sustained unresponsiveness to milk oral immunotherapy using epitope-specific antibody binding profiles
BACKGROUND: In a recent trial of milk oral immunotherapy (MOIT) with or without omalizumab in 55 patients with milk allergy treated for 28 months, 44 of 55 subjects passed a 10-g desensitization milk protein challenge; 23 of 55 subjects passed the 10-g sustained unresponsiveness (SU) challenge 8 wee...
保存先:
| 出版年: | J Allergy Clin Immunol |
|---|---|
| 主要な著者: | , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7658687/ https://ncbi.nlm.nih.gov/pubmed/30528770 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jaci.2018.10.028 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|